<DOC>
	<DOCNO>NCT01751022</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Medtronic Attain Performa Quadripolar Leads ( Model 4298 , 4398 , 4598 ) post implant procedure . This study also assess interaction Attain Performa lead entire Medtronic CRT-D system .</brief_summary>
	<brief_title>Attain Performa ( TM ) Quadripolar Lead Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patient indicate implant CRTD device leftheart lead per local indication ( In US base Class I II indication CRTD implant per HRS/ACC/AHA guideline ) Patient ( legally authorize representative ) sign date studyspecific Consent Form Patient 18 year age old , legal age give inform consent per local national law Patient expect remain available followup visit Patient understand study agree comply study protocol Patient previous LV lead implant previous implant attempt within 30 day enrollment ongoing AEs previous unsuccessful implant attempt Patient contraindication standard transvenous cardiac pacing ( e.g. , mechanical right heart valve ) Patient heart transplant ( Note : Patients wait heart transplant allow study ) Patient contraindicate &lt; 1 mg dexamethasone acetate Patient currently enrol plan participate potentially confound drug device study course study . ( Note : Coenrollment concurrent study may allow provide documented preapproval obtain Medtronic 's study manager ) Patient life expectancy le 180 day Patient exclusion criterion require local law ( e.g . age , pregnancy , breast feeding , etc . ) In US , woman childbearing potential must negative pregnancy test 7 day prior implant include Patient unable tolerate urgent thoracotomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>heart failure</keyword>
	<keyword>cardiac pacing</keyword>
	<keyword>cardiac resynchronization therapy</keyword>
	<keyword>leave ventricular lead</keyword>
</DOC>